MedTrace Logo

Blood Leukocyte Profiling in Eosinophilic Type 2 Asthma: Influence of Systemic IL-5 Targeting

NCT05689931 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-01-19

No results posted yet for this study

Summary

The goal of this exploratory and observational prospective study is to study the composition and phenotypes of blood leukocytes collected from asthmatic patients before and after instantiated treatment with the interleukin-5 neutralizing antibody mepolizumab. Comparisons will be made to leukocyte profiles in patients already on mepolizumab treatment, asthma patients without any biological treatment, and non-diseased control subjects.

Conditions

Interventions

BIOLOGICAL

Mepolizumab

Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma. Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

DRUG

Standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

Sponsors & Collaborators

  • Lund University

    collaborator OTHER

  • Region Skane

    lead OTHER

Principal Investigators

  • Jonas Erjefält · Lund University Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2024-04-01
Completion
2024-12-18
FDA Drug
Yes

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05689931 on ClinicalTrials.gov